Lantern Pharma Inc.

NASDAQ:LTRN

Biotechnology

Healthcare
$3.93 -4.67%

-$0.19 today

Market cap
$50.14M
Beta
2.32
P/E (TTM)
-2.7
EPS (TTM)
-$1.41
52W Low $1.11High $5.74

Volume 0.10M

Average 0.68M

LTRN Financing Cash Flow

Net cash exchanged with lenders and shareholders through borrowing, repayments, buybacks, and dividends.

Lantern Pharma Inc.NASDAQ: LTRN

Financing Cash Flow · Q1 FY2026 · quarter ended Mar 2026

Financing cash flow outflow grows to $0

Q1 FY2026 financing cash flow was $0, compared with $0 a year earlier. Trailing-twelve-month financing cash flow was $1.5M.

Context

  • Financing cash flow increased in 3 of the last 3 fiscal years.
  • FY2025 was the highest annual figure in the 4 fiscal years shown.

What to watch

Whether quarterly financing cash flow holds near $0 or moves back toward the trailing-twelve-month quarterly average of $374.56K.

Sources:Cash FlowText generated from reported figures; not investment advice.

Latest quarterMar 2026
$0-100.0% QoQ
Last fiscal yearDec 2025
$1.5M+2145.9% YoY
LTMMar 2026
$1.5M+12391.6% YoY
Financing Cash Flow past and forecast growth by horizon
Horizon Past Forecast Difference
Quarter———
1 year+2145.9%——
3-year CAGR———
5-year CAGR——
10-year CAGR——

Financing Cash Flow history

USD · from the cash flow

Latest · FY2025
1.5M USD
Year-over-year change
+2145.9%
4-year CAGR
-60.8%

Financing Cash Flow vs competitors

How LTRN compares with its peers on the latest reported figures

  • LTRN's LTM Mar 2026 financing cash flow of $1.5M is the 4th largest of the 5 companies compared; the peer median is $13.8M.
  • Its year-over-year change of +12391.6% is the highest of 5, against a peer median of -55.9%.
LTRN Competitors Peer median
Financing Cash Flow for LTRN and competitors
Company Period LTM YoY 3-year CAGR% of revenue
MAIAMAIA Biotechnology, Inc.LTM Mar 2026$43.5M +129.9%+12.8%—
ANVSAnnovis Bio, Inc.LTM Mar 2026$18.52M -56.0%+19474.8%—
RNXTRenovoRx, Inc.LTM Mar 2026$9.08M -55.7%+536.8%609.9%
LTRNLantern Pharma Inc.LTM Mar 2026$1.5M +12391.6%——
ATNMActinium Pharmaceuticals, Inc.LTM Jun 2026$217K -104.7%—0.6%
Peer median (excluding LTRN) $13.8M-55.9%+536.8%305.2%

Competitors are the stored peer set for LTRN. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Cash Flow Statement

USD
Metric
FY2021
Dec 2021
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Net Income(12.36M)(14.26M)(15.96M)(20.78M)(17.12M)
Depreciation & Amortization6.76K10.08K14.62K190.49K17.28K
Deferred Income Tax00000
Stock-Based Compensation961.55K1.19M1.07M0650.88K
Change in Working Capital599.96K(611.86K)538.02K2.23M635.28K
Accounts Receivables000(175.72K)0
Inventory00000
Accounts Payables0001.64M0
Other Working Capital599.96K(611.86K)538.02K767.44K635.28K
Other Non-Cash Items203.22K906.49K(5.17K)549.36K139.02K
Operating Cash Flow(10.59M)(12.77M)(14.35M)(17.81M)(15.68M)
Capital Expenditures(15.5K)(27.84K)(18.73K)(12.6K)(1.72K)
Acquisitions (Net)00000
Purchases of Investments(19.58M)(3.91M)(8.2M)(17.28M)(14.72M)
Sales of Investments64.09K4.12M7.28M20.66M25.78M
Other Investing Activities00000
Investing Cash Flow(19.53M)179.27K(930.21K)3.37M11.06M
Debt Repayment00000
Common Stock Issued69M0066.71K1.64M
Common Stock Repurchased0(2.48M)(500K)00
Dividends Paid00000
Other Financing Activities(4.64M)2.78M00(139.75K)
Financing Cash Flow63.42M(2.18M)(500K)66.71K1.5M
Effect of Forex Changes1.07K(10.61K)(28.46K)(49.55K)33.43K
Net Change in Cash33.3M(14.78M)(15.81M)(14.43M)(3.09M)
Free Cash Flow(10.61M)(12.8M)(14.37M)(17.83M)(15.68M)

Lantern Pharma Inc.

NASDAQ:LTRN

Intrinsic Alpha fair value

Locked

Current Price

$3.93

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.